Physician profile
Brian Pierson
NPI 1780767319
$2,723.18
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,165 · 2020: $232 · 2021: $616 · 2022: $689 · 2023: $21.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $406.73 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $376.19 | 2019-2022 | |
| Amgen INC. | $261.27 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $144.07 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $138.33 | 2021 | |
| Collegium Pharmaceutical, INC. | $128.37 | 2019-2022 | |
| Assertio Therapeutics, INC. | $126.26 | 2019 | |
| Supernus Pharmaceuticals, INC. | $119.66 | 2019-2020 | |
| Lilly USA, LLC | $108.88 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $107.95 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $94.06 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.30 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $78.08 | 2019 | |
| Upsher-Smith Laboratories LLC | $74.10 | 2021-2022 | |
| Grt US Holding, INC. | $52.70 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $45.87 | 2019-2020 | |
| Si-Bone, INC. | $29.61 | 2019-2021 | |
| Forte Bio-Pharma LLC | $28.17 | 2021 | |
| Daiichi Sankyo INC. | $26.98 | 2019 | |
| Mdd US Operations, LLC | $25.97 | 2019 | |
| Zyla Life Sciences, INC. | $24.46 | 2019 | |
| Ibsa Pharma INC. | $24.27 | 2022 | |
| Biodelivery Sciences International, INC. | $23.80 | 2019-2021 | |
| Boston Scientific Corporation | $21.91 | 2023 | Wavewriter Alpha Prime 16 |
| Impel Pharmaceuticals INC. | $21.23 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.72 | 2022 | |
| Hikma Pharmaceuticals USA | $18.41 | 2022 | |
| Protega Pharmaceutials INC | $16.15 | 2022 | |
| Electronic Waveform Lab, INC. | $16.07 | 2019 | |
| Almatica Pharma LLC | $15.23 | 2021 | |
| Biogen, INC. | $14.30 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.89 | 2019 | |
| Shionogi INC | $12.89 | 2019 | |
| Allergan, INC. | $12.17 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Pierson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.